Psychometric Properties of the COVID-19 Vaccine Anxiety Scale for Adults
الملخص
Objective: The SARS-CoV-2 pandemic has been a huge challenge for the world's public health and has led to morbid fear and anxiety in many individuals. Further, many people maintain doubts and anxiety about receiving COVID-19 vaccinations due to psychological distortions regarding their effectiveness and safety. Ongoing research is designed to measure the psychometric properties of the COVID-19 Vaccine Anxiety Scale (CVAS), an instrument designed to measure fear and anxieties regarding COVID-19 vaccinations.
Methods: Three experimental stages were conducted. The first was to refine the items along the three dimensions of somatic, psychological, and behavioral symptoms. It included 450 participants, whereas the main experiment had 1296 participants, who completed the CVAS questionnaire as well as the Satisfaction with Life Scale (Diener et al., 1985). Explanatory and confirmatory factor analyses and internal consistency analyses were performed to measure reliability.
Results: The Cronbach Alpha reliability coefficients of the scale’s three dimensions i.e., Physiological (Somatic), Psychological and Behavioral Symptoms were calculated as a = 0.91, 0.88, and 0.69, respectively. Factor loadings on the items belonging to each of the three factors varied between 0.62, 0.901, and 0.91. Also, the CVAS was negatively correlated with the Satisfaction with Life Scale as r = -0.325; p<0.001.
Conclusions: CVAS is a valid and reliable measure. This study can be used as a reference for future research and practice in measuring anxiety about COVID-19 vaccination. Screening individuals with CVAS can support improvement of life satisfaction for individuals and community mental health.
المراجع
2. Balaratnasingam, S., & Janca, A. (2006). Mass hysteria revisited. Current Opinion in Psychiatry, 19(2), 171-174.
3. Bendau, A., Plag, J., Pwtzold, M. B., & Ströhle, A. (2021) COVID-19 vaccine hesitancy and related fears and anxiety. International Immunopharmacology, 97, https://doi.org/10.1016/j.intimp.2021.107724
4. Bo, H. X., Li, W., Yang, Y., Wang, Y. U., Zhang, Q., Cheung, T., ... & Xiang, Y. T. (2021). Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine, 51(6), 1052-1053.
5. Briggs, S. R., & Cheek, J. M. (1988). On the nature of self-monitoring: Problems with assessment, problems with validity. Journal of Personality and Social Psychology, 54(4), 663-678.
6. De Vaus, D. (2002). Surveys in social research (5th Edition.). London: UCL Press and Routledge.
7. Diener, E. D., Emmons, R. A., Larsen, R. J., & Griffin, S. (1985). The Satisfaction With Life Scale. Journal of Personality Assessment, 49(1), 71-75. https://doi.org/10.1207/s15327752jpa4901_13
8. Duncan, L. A., Schaller, M., & Park, J. H. (2009). Perceived vulnerability to disease: Development and validation of a 15-item self-report instrument. Personality and Individual Differences, 47(6), 541-546.
9. Fadhel, F. H., Sufyan, N. S., Alqahtani, M. M. J., & Al Maamari, A. A. (2024). Anxiety and fear of COVID-19 as potential mechanisms to explain vaccine hesitancy among adults. Frontiers in Psychiatry, 15, https://doi.org/10.3389/fpsyt.2024.1376567
10. Gosling, S. D., Rentfrow, P. J., & Swann Jr, W. B. (2003). A very brief measure of the Big-Five personality domains. Journal of Research in Personality, 37(6), 504-528.
11. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Zhong, N. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine, 382(18), 1708-1720.
12. Hair, J., Black, W., Babain, B., & Anderson, R. (2010) Multivariate data analysis (7th ed.). Pearson, Prentice-Hall.
13. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497-506.
14. Islam M. A., Alshayban, D. M., Naqvi, A. A., Maqsood, M. B., Ishaqui, A. A., Kashif, M., Ali, M., & Haseeb, A. (2023). How anxiety attributed to COVID-19, disease knowledge, and intention to vaccinate against SARS-CoV-2 viral infection prevail in general public of Saudi Arabia? Frontiers in Public Health, 11, https://doi.org/10.3389/fpubh.2023.1078023
15. Jansson, B. S., Nyamathi, A., Duan, L., Kaplan, C., Heidemann, G., & Ananias, D. (2015). Validation of the patient advocacy engagement scale for health professionals. Research in Nursing & Health, 38(2), 162-172.
16. Lee S. A. (2020). Coronavirus Anxiety Scale: A brief mental health screener for COVID-19 related anxiety. Death Studies, 44(7), 393–401.
17. Li, L. Q., Huang, T., Wang, Y. Q., Wang, Z. P., Liang, Y., Huang, T. B., Zhang, H. Y., Sun, W. M., & Wang, Y. P. (2020). Response to Char's comment: Comment on Li et al: COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. Journal of medical virology, 92(9), 1433. https://doi.org/10.1002/jmv.25924
18. Marra, A. R., Kobayashi, T., Callado, G. Y., Pardo, I., Gutfreund, M. C., Hsieh, M. K., … & Rizzo, L. V., (2023). The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research. Antimicrobial Stewardship & Healthcare Epidemiology, 3, e168, 1–16, doi:10.1017/ash.2023.447
19. Mintz, K., Jardas, E., Shah, S., Grady, C., Danis, M., & Wendler, D. (2021). Enrolling minors in COVID-19 vaccine trials. Pediatrics, 147(3). https://doi.org/10.1542/PEDS.2020-040717
20. Pallant, J. (2010). SPSS survival manual (4th Edition). England: Open University Press.
21. Park, J. J., Decloedt, E. H., Rayner, C. R., Cotton, M., & Mills, E. J. (2020). Clinical trials of disease stages in COVID 19: Complicated and often misinterpreted. The Lancet Global Health, 8(10), e1249-e1250.
22. Preacher, K. J., & MacCallum, R. C. (2002). Exploratory factor analysis in behavior genetics research: Factor recovery with small sample sizes. Behavior genetics, 32(2), 153-161.
23. Roehr, B. (2013). American Psychiatric Association explains DSM-5. BMJ, 346, f3591. https://doi.org/10.1136/bmj.f3591
24. Tavşancil, E., & Keser, H. (2002). Development of a Likert-type attitude scale for internet use. Journal of Educational Sciences & Practices, 1(1), 79-100.
25. Thompson, B. (2004). Exploratory and confirmatory factor analysis: Understanding concepts and applications. US: American Psychological Association.
26. Wang, D. et al., (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Journal of the American Medical Association, 323, 1061-10691
27. Wei, W. E., Li, Z., Chiew, C. J., Yong, S. E., Toh, M. P., & Lee, V. J. (2020). Presymptomatic transmission of SARS-CoV-2—Singapore, January 23–March 16, 2020. Morbidity and Mortality Weekly Report, 69(14), 411.
28. World Health Organization. (2021). COVID-19 cases WHO COVID-19 dashboard. From https://data.who.int/dashboards/covid19/cases?n=https://data.who.int/dashboards/covid19/cases?n=c
29. Xiong, S., Liu, X., Deng, W., Zhou, Z., Li, Y., Tu, Y., Chen, L., Wang, G., & Fu, B. (2020). Pharmacological Interventions for Bacterial Prostatitis. Frontiers in Pharmacology, 11, 504.
30. Yang, J., Zheng, Y. A., Gou, X., Pu, K., Chen, Z., Guo, Q., ... & Zhou, Y. (2020). Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. International Journal of Infectious Diseases, 94, 91-95.
